Inventor · disambiguated record
Ivan Perrot
Also filed as: PERROT IVAN
8 granted patents·14 pending applications·19 citations·filing 2013–2025
82Inventor score
Top patents by PatentIndex Score
22 records- 0196US11958907B2CD73 blockadeINNATE PHARMA·Filed 2020·Granted Apr 16, 2024·4 cites·21 claims
- 0289US11377503B2Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptideINNATE PHARMA·Filed 2019·Granted Jul 5, 2022·3 cites·13 claims
- 0389US10766966B2CD73 blockadeINNATE PHARMA·Filed 2015·Granted Sep 8, 2020·5 cites·12 claims
- 0483US11130817B2CD73 blocking agentsINNATE PHARMA·Filed 2016·Granted Sep 28, 2021·3 cites·5 claims
- 0579US12202907B2Nucleic acids encoding and methods of producing proteins comprising antibody chainsINNATE PHARMA·Filed 2022·Granted Jan 21, 2025·0 cites·36 claims
- 0677US11578136B2Compositions and methods for treating cancerINNATE PHARMA·Filed 2018·Granted Feb 14, 2023·1 cites·12 claims
- 0777US10577416B2Mica binding agentsINNATE PHARMA SA·Filed 2013·Granted Mar 3, 2020·3 cites·3 claims
- 0873US2023340143A1Compositions and methods for treating cancerINNATE PHARMA·Filed 2023·Application pending·0 cites
- 0971US2025236678A1Compositions and methods for treating cancerINNATE PHARMA·Filed 2025·Application pending·0 cites
- 1070US2023099801A1Restoration of t cell activity via the cd39/cd73 axisINNATE PHARMA·Filed 2022·Application pending·0 cites
- 1165US2022056145A1Anti-cd39 antibodiesOREGA BIOTECH·Filed 2021·Application pending·0 cites
- 1258US2020299380A1Mica binding agentsINNATE PHARMA·Filed 2020·Application pending·0 cites
- 1357US2019071514A1Anti-cd39 antibodiesINNATE PHARMA·Filed 2017·Application pending·0 cites
- 1457US2022025056A1Leucocyte immunoglobulin-like receptor neutralizing antibodiesINNATE PHARMA·Filed 2019·Application pending·0 cites
- 1557US2022025045A1Compounds and methods for treatment of head and neck cancerINNATE PHARMA·Filed 2019·Application pending·0 cites
- 1655US2024270865A1Cancer treatment methods using anti-cd73 antibodiesINNATE PHARMA·Filed 2021·Application pending·0 cites
- 1750US2024294634A1Treatment of cancer with ilt-2 inhibitorsINNATE PHARMA·Filed 2020·Application pending·0 cites
- 1849US2019218308A1Restoration of t cell activity via the cd39/cd73 axisINNATE PHARMA·Filed 2019·Application pending·0 cites
- 1945US2019218304A1Potentiating the effect of atp releaseINNATE PHARMA·Filed 2019·Application pending·0 cites
- 2044US9944712B2TLR3 binding agentsINNATE PHARMA·Filed 2013·Granted Apr 17, 2018·0 cites·28 claims
- 2138US2019153113A1Cd39 vascular isoform targeting agentsINNATE PHARMA·Filed 2016·Application pending·0 cites
- 2236US2018030144A1Cd73 blockadeINNATE PHARMA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ivan Perrot files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →